Hereditary tyrosinemia. Formation of succinylacetone-amino acid adducts.
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Succinylacetone (SA) (4,6-dioxoheptanoic acid) is an abnormal metabolite produced in patients with hereditary tyrosinemia as a consequence of an inherited deficiency of fumaryl acetoacetate hydrolase activity. Patients with this disease are associated with a number of abnormalities, including aminoaciduria, proteinuria, liver failure, commonly hepatoma, and decreased GSH concentration in the liver. In the course of our studies of tyrosinemia, we found that the urine of patients with this disorder contains material(s) that absorbs light at 315 nm. We investigated the nature of the 315 nm material in detail. SA was found to react with amino acids and protein nonenzymatically, to form stable adducts at physiological temperature and pH. All SA adducts with amino acids and/or proteins exhibited an absorption peak at 315 nm. Although all amino acids reacted with SA, the most reactive amino acid was lysine (Lys), followed, in order, by glycine, methionine, phenylalanine, serine, alanine, and glutamine. SA-adducts were unstable at pH below 6, while they were made considerably more stable after reduction with NaBH4, suggesting that SA forms an adduct via Schiff base formation. High-performance liquid chromatography (HPLC) analysis of urines from patients with tyrosinemia revealed the existence of SA-glycine, SA-methionine, SA-tyrosine, and SA-phenylalanine. After digestion of urines with proteinase K, three more HPLC peaks appeared, which all corresponded to SA-Lys adducts. TLC analysis of SA-Lys showed that SA-Lys could form as many as seven different adducts. No SA-adduct peaks were observed in HPLC in urines from normal subjects, patients with other forms of aminoaciduria, or patients with the nephrotic syndrome. In addition to amino acids and proteins, SA reacted with reduced glutathione (GSH) and formed a stable adduct. These findings suggest that SA adduct formation with amino acids, GSH, and proteins is a significant process occurring in tyrosinemia, and may account for certain of the pathologic findings in this hereditary disorder.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
On the enzymic defects in hereditary tyrosinemia.
Lindblad, B., Lindstedt, S., & Steen, G. (1977) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.74.10.4641 · Cited by 447 · cited 2×
“SA in biological fluids can be determined by gas chromatography (4, 5) or indirectly by inhibition of 6aminolevulinic acid (ALA) dehydratase, because the compound is an extremely potent inhibitor of this enzyme in human as well as in animal tissues (6, 7).”
BackgroundMethodThe occurrence of hepatoma in the chronic form of hereditary tyrosinemia
Weinberg, A. G., Mize, C. E., & Worthen, H. G. (1976) · The Journal of Pediatrics · doi:10.1016/s0022-3476(76)80259-4 · Cited by 283
Sassa, S., & Kappas, A. (1983) · Journal of Clinical Investigation · doi:10.1172/jci110809 · Cited by 145 · cited 2×
“SA in biological fluids can be determined by gas chromatography (4, 5) or indirectly by inhibition of 6aminolevulinic acid (ALA) dehydratase, because the compound is an extremely potent inhibitor of this enzyme in human as well as in animal tissues (6, 7).”
BackgroundMethodSelf-citationInhibition of delta-aminolevulinic acid dehydrase by 4,6-dioxoheptanoic acid.
Tschudy, D. P., Hess, R. A., & Frykholm, B. C. (1981) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)68717-x · Cited by 113
Grenier, A., Lescault, A., Laberge, C., Gagné, R., & Marner, O. (1982) · Clinica Chimica Acta · doi:10.1016/0009-8981(82)90117-6 · Cited by 73 · cited 3×
“Patients with this hereditary disease excrete large amounts of 4,6-dioxoheptanoic acid (succinylacetone [SA]) (4), and the presence o f SA is thought to be a specific biochemical marker of this disease.”
BackgroundMethodGENTZ, J. (1967) · American Journal of Diseases of Children · doi:10.1001/archpedi.1967.02090160081006 · Cited by 53
Cited by
Klebig, M. L., Russell, L. B., & Rinchik, E. M. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.4.1363 · Cited by 65
Sander, J., Janzen, N., Peter, M., Sander, S., Steuerwald, U., Holtkamp, U., Schwahn, B., Mayatepek, E., Trefz, F. K., & Das, A. M. (2006) · Clinical Chemistry · doi:10.1373/clinchem.2005.059790 · Cited by 62
“Under the conditions given, hydrazine is thought to cleave covalently linked SA-protein adducts ( 4 ) and to simultaneously form a hydrazone derivative (Fig. 1), which is extracted (5).”
BackgroundDisorders of Tyrosine Metabolism
Chakrapani, A., & Holme, E. (2006) · Inborn Metabolic Diseases · doi:10.1007/978-3-540-28785-8_18 · Cited by 52
Disorders of Tyrosine Metabolism
Chakrapani, A., Gissen, P., & McKiernan, P. (2012) · Inborn Metabolic Diseases · doi:10.1007/978-3-642-15720-2_18 · Cited by 17
Metadata
- Authors
- Manabe, S., Sassa, S., & Kappas, A.
- Venue
- The Journal of experimental medicine
- Publisher
- Rockefeller University Press
- Published
- 1985-09-01
- Volume
- 162
- Issue
- 3
- Pages
- 1060-1074
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2048593112
- Cited by
- 40
- References
- 6
- FWCI
- 0.61
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Hereditary tyrosinemia. Formation of succinylacetone-amino acid adducts. https://app.cochat.ai/papers/10.1084/jem.162.3.1060
- The paper
- Manabe, S., Sassa, S., & Kappas, A. (1985). Hereditary tyrosinemia. Formation of succinylacetone-amino acid adducts. The Journal of experimental medicine. https://doi.org/10.1084/jem.162.3.1060
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.